Brucellosis Market Size:
The brucellosis market size is growing with a CAGR of 6.7% during the forecast period (2025-2032), and the market is projected to be valued at USD 508.13 Million by 2032 from USD 303.46 Million in 2024. Additionally, the market value for the 2025 attributes to USD 322.72 Million.
Brucellosis Market Scope & Overview:
Brucellosis is a bacterial disease caused by the brucella species which primarily affects the livestock such as cattle, goats, sheep, and pigs. The different brucella species involved are brucella melitensis, brucella suis, brucella abortus, and brucella canis. Brucellosis spreads to humans through direct contact with infected animals and consumption of unpasteurized dairy products. The disease is characterized by fever, fatigue, joint pain, and sweating. Brucellosis is diagnosed through various methods such as culture, serological tests, bone marrow biopsy, and others. Treatment for the disease includes antibiotics and vaccines. Additionally, diagnostic tools such as MALDI-TOF mass spectrometry is enabling early diagnosis of brucellosis among patients further diving the market growth.
How is AI Transforming the Brucellosis Market?
AI is playing a crucial role in the brucellosis market, particularly in areas involving disease prediction, diagnosis, and control strategies. AI-powered solutions are being employed to analyze data and improve the accuracy of brucellosis prediction, identify risk factors, and optimize control measures. Moreover, AI solutions can enhance the accuracy of brucellosis diagnosis by analyzing various data points such as diagnostic tests, blood tests, personal features, and disease symptoms.
Additionally, AI-powered simulation models are being used to assess the efficiency of different diagnostic systems for detecting brucellosis, which further optimizes resource allocation and improves the overall effectiveness of control programs. Therefore, the above factors are expected to positively impact the market growth in the upcoming years.
Brucellosis Market Dynamics - (DRO) :
Key Drivers:
Growing Prevalence of Brucellosis is Driving Brucellosis Market Growth
Brucellosis is a bacterial disease caused by Brucella bacteria. It spreads from animals to humans, mostly by unpasteurized dairy products. The disease is diagnosed with the help of culture, serological tests, bone marrow biopsy, and others. Treatment involves antibiotics and vaccines. The prevalence of brucellosis is growing due to growing livestock population, lack of pasteurization, and growing involvement in farming.
- In 2022, according to European Centre for Disease Prevention and Control, the brucellosis cases in Europe is increased by 20% as compared to the year 2021. This has increased the visits for diagnosis and treatment, thus driving the market.
Thus, the growing prevalence of brucellosis is leading to brucellosis market demand through advanced diagnostics and treatment options.
Technological Advancements are Creating Brucellosis Market Demand
Technological advancements are changing the landscape of the market. It includes advanced enzyme-linked immunosorbent assay (ELISA), and MALDI-TOF mass spectrometry. ELISA detects anti-brucella antibodies thereby confirming the presence of the disease in the body. Further, MALDI-TOF mass spectrometry included broad coverage of the brucella genus together with species-level identification. Due to increasing demand for advanced diagnostic methods in the brucellosis, companies are increasing the production of their systems.
- In 2024, Bruker Corporation launched neofleX MALDI-TOF System. This system is used for brucellosis identification from culture plates and directly from blood culture bottles. The neofleX MALDI-TOF System features reimagined fragmentation module that enhance sensitivity, speed and sequence coverage during diagnosis.
Thus, technological advancements are leading to brucellosis market expansion due to advanced diagnosis of the disease.
Key Restraints:
Stringent Rules and Regulations are Constraining Brucellosis Market Growth
Rules and regulations are significantly restraining the market due to stringent requirements for the approval of diagnostics tools and new drugs. There is lengthy and complex approval processes for new medications. It delays the introduction of innovative treatments, limiting treatment options for brucellosis patients. Regulatory agencies such as United States Food and Drug Administration, European Medicines Agency, and others require extensive clinical trials and data before granting approval to vaccines. Additionally, government impose stringent guidelines on livestock movement, trade, and vaccination programs to prevent disease spread. Thus, rules and regulations are constraining the market growth due to regulatory standards and complex approval processes for new medications.
Future Opportunities :
Rising Government Initiatives are Expected to Create Brucellosis Market Opportunities
The government initiatives are creating potential for markets as they aimed at supporting the prevention, control, and elimination of brucellosis. The surveillance programs are providing legal framework for controlling animal brucellosis. Further, these programs are helping countries to assess their capacities and develop strategies. To control the disease, the governments around the globe are arranging workshops as well.
- In 2025, Food and Agriculture Organization of the United Nations in collaboration with the Centers for Disease Control and Prevention hosted brucellosis progressive control workshop in Europe. This workshop introduced the Stepwise Approach for Progressive Control of Brucellosis (SAPCB) and the Staged Tool for the Elimination of Brucellosis (STEB).
Thus, rising government initiatives are expected to create brucellosis market opportunities through advanced surveillance programs and workshops.
Brucellosis Market Segmental Analysis :
By Species:
Based on species, the market is categorized into brucella melitensis, brucella suis, brucella abortus, and brucella canis.
Trends in Species:
- According to brucellosis market trends, brucella melitensis causes severe human brucellosis due to highest zoonotic potential.
- Cases of Brucella suis is growing due to environmental resistant and survival in freezing temperatures as per market trends.
The brucella melitensis segment accounted for the largest market share in the year 2024.
- Brucella melitensis is a gram-negative coccobacillus in the family Brucellaceae which causes brucellosis mainly in sheep and goats.
- This species has the highest zoonotic potential compared to other species which causes severe human brucellosis cases worldwide.
- There are multiple lineages of brucella melitensis which causes human brucellosis epidemic.
- For instance, in 2024, according to research article published in Frontiers, multiple lineages of brucella melitensis such as clade A and clade B are leading to human brucellosis in China. To identify these lineages conventional bio-typing approach and whole genome sequencing of single-nucleotide polymorphisms (SNPs) were employed to identify 189 strains.
- Thus, brucella melitensis is dominating species in the market due to highest zoonotic potential and multiple lineages.
The brucella suis segment is expected to grow at the fastest CAGR over the forecast period.
- Brucella suis is a gram-negative coccobacillus in the family brucellaceae which causes brucellosis mainly in pigs.
- This species includes mainly biovars 1, 2 and 3 causing infertility in the pigs.
- Brucella suis bacteria are moderately resistant to environmental influences and survives in desiccation and freezing & near-freezing temperatures.
- Further, these bacteria is transmitted through alimentary or genital tract of infected pigs to susceptible pigs.
- The brucella suis is also transmitted in infectious semen during natural breeding and artificial insemination in pigs.
- Thus, brucella suis species is growing in the market, due to resistance to environmental influences.
By Type:
Based on type, the market is categorized into diagnosis and treatment.
Trends in Type:
- As per brucellosis market trends, advanced serological tests are improving early and confirm diagnosis of the disease.
- Use of vaccines is growing for the prevention and spread of brucellosis as per market trends.
The diagnosis segment accounted for the largest market share in the year 2024.
- Diagnosis is further categorized into culture, serological tests, bone marrow biopsy, and others.
- In bone marrow biopsy, a liver aspiration is taken from the bone marrow or blood to check the presence of the bacteria.
- While culture is recommended for fever of unknown origin, negative serology, and unexplained articular or hematologic involvement.
- Further, the most commonly used serological tests for the diagnosis of human brucellosis are the serum agglutination test (SAT), the rose Bengal test (RBT), the coombs test and ELISA.
- Hence, diagnostic methods such as culture and bone marrow biopsy help in the early and confirm diagnosis of brucellosis.
The treatment segment is expected to grow at the fastest CAGR over the forecast period.
- Treatment is further categorized into antibiotics and vaccines. Antibiotics such as doxycycline, gentamicin, streptomycin, rifampin, and trimethoprim-sulfamethoxazole are used in the treatment.
- The development of vaccines for disease involved the use of inactivated, live-attenuated, and rough-attenuated vaccines.
- Additionally, the governments are conducting brucellosis vaccination camp to control the further spread of the disease among the animals.
- For instance, in 2024, Government of Tamilnadu, conducted brucellosis vaccination camp across veterinary hospital, veterinary dispensaries, and veterinary branches in India.
- Therefore, vaccination camps are enabling the prevention and spread of the brucellosis thereby driving the segment.
By End-User:
Based on end-user, the market is categorized into hospitals, clinics, academic institutes, and others.
Trends in End-User:
- As per market trends, hospitals are widely adopting advanced diagnostic and treatment options providing comprehensive care to the affected patients.
- Preference for clinics is growing among patients due to cost effectiveness and accessibility as per market trends.
The hospitals segment accounted for the largest market share of 56.35% in the year 2024.
- A hospital is a healthcare facility that provides medical and nursing care as well as medical supplies to patients.
- Hospitals play a major role in the market due to their well-established infrastructure and advanced imaging technologies.
- Due to rising cases of brucellosis, investment in hospitals is growing for early diagnosis and treatment among the patients.
- For instance, in 2023, according to India Brand Equity Foundation, an amount of USD 1.5 billion is invested in hospitals in India by foreign direct investment. This investment includes building new hospitals and advancing existing hospitals for the diagnosis and treatment of various diseases including brucellosis.
- Thus, hospitals are dominating in the market due to advanced infrastructure and modern imaging technologies.
The clinics segment is expected to grow at the fastest CAGR over the forecast period.
- Clinics are healthcare facilities which offer diagnostic, therapeutic, or preventive outpatient services.
- They are becoming more involved in the early detection and diagnosis of brucellosis.
- Clinics offer more accessible, cost-effective options for managing the disease, reducing the need for extended hospital stays.
- As healthcare systems focus on providing more outpatient services, clinics are increasingly being utilized for regular follow-ups, disease management.
- The demand for clinics is rising, supported by the growing number of brucellosis cases due to growing livestock population, lack of pasteurization, and growing involvement in farming.
- Thus, clinics segment is growing in the market due to increased accessibility and quality of care for the patients.
Regional Analysis:
The regional segment includes North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
In 2024, North America accounted for the highest market share at 41.22% and was valued at USD 125.09 Million and is expected to reach USD 194.75 Million in 2032. In North America, United States accounted for the highest market share of 71.52% during the base year of 2024.
The brucellosis market share of the North America region is major due to technological advancements. Technological advancements such as MALDI-TOF mass spectrometry and bispecific ELISA test have enhanced the diagnosis and treatment of the disease. Further, rising government investment in research initiatives for the brucellosis is driving the market in the region.
- In 2022, National Institute of Health invested 2.75 million in Washington State University. This amount is used for exploring how bacterial proteins work together to cause transmission of brucellosis for animals to humans.
Thus, North America is leading in the market due to technological advancements and research initiatives as per market analysis.
Asia-pacific is expected to witness the fastest CAGR of 8.6% over the forecast period of 2025-2032. According to brucellosis market analysis, the Asia Pacific region is growing rapidly driven by high livestock population and rising dairy consumption. Countries such as China, India, Japan, and South Korea are major contributors in the market with large-scale consumption of dairy products including cheese, butter, and others. These countries are levering livestock and large-scale manufacturing for the production of dairy products leading to increased cases of brucellosis. Hence, brucellosis market share of Asia Pacific is experiencing rapid growth through large scale livestock population and rising dairy consumption as per analysis.
As per brucellosis market analysis, the Europe region is growing rapidly in the market driven by stringent control measures. This includes routine livestock testing and compensation for infected animals. Further, the region has strong veterinary infrastructure and public awareness campaigns. It is contributing to the disease management and eradication of the brucellosis further driving the market growth.
The Middle East and Africa region is experiencing gradual growth in the market, driven by rising cases of brucellosis. Countries such as Saudi Arabia, Oman, and Iraq are major contributors due to growing prevalence of the disease. Unregulated livestock trade and widespread consumption of unpasteurized dairy has further led the spread of the brucellosis. Additionally, social and political instabilities, insufficient resources for appropriate diagnosis, reporting of cases is further diving the market demand as per analysis.
As per analysis, the market in Latin America is driven by growing livestock trade and government initiatives. Countries such as Brazil, Mexico and Argentina are major contributors in the region due to expansion of cattle farming and dairy industry. Governments are investing in the surveillance programs and vaccination camps for the diagnosis and treatment of infectious diseases among livestock. It is driving brucellosis market expansion in the region.
Top Key Players and Market Share Insights:
The brucellosis industry is highly competitive with major players providing products to the national and international markets. Key players are adopting several strategies in research and development (R&D) and product innovation to hold a strong position in the global brucellosis market. Key players in brucellosis industry include-
- HESTER BIOSCIENCES LIMITED (India)
- Merck & Co., Inc. (United States)
- Veterinary Technologies Corporation (United States)
- China Animal Husbandry Co., Ltd. (China)
- Calier & Biologicos Laverlam (Spain)
- Dollvet (Turkey)
- Colorado Serum Company (United States)
- Biogénesis-Bagó S.A. (Argentina)
- ATA FEN Inc. (Turkey)
- Fresenius SE & Co. KGaA (Germany)
Recent Industry Developments :
Partnerships and Collaborations
- In 2022, Food and Agriculture Organization of the United Nations collaborated with government of Kenya, Zoonotic Diseases Unit (ZDU) and other One Health sector stakeholders. Through this collaboration they launched National Strategy for the prevention and control of brucellosis in humans and animals in Kenya.
Brucellosis Market Report Insights :
| Report Attributes | Report Details |
| Study Timeline | 2019-2032 |
| Market Size in 2032 | USD 508.13 Million |
| CAGR (2025-2032) | 6.7% |
| By Species |
|
| By Type |
|
| By End User |
|
| By Region |
|
| Key Players |
|
| North America | U.S. Canada Mexico |
| Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
| APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
| Middle East and Africa | GCC Turkey South Africa Rest of MEA |
| LATAM | Brazil Argentina Chile Rest of LATAM |
| Report Coverage |
|
Key Questions Answered in the Report
How big is the brucellosis market? +
In 2024, the brucellosis market is USD 303.46 million.
Which is the fastest-growing region in the brucellosis market? +
Asia Pacific is the fastest-growing region in the brucellosis market.
What specific segmentation details are covered in the brucellosis market? +
Species, Type, and End-User are covered in the brucellosis market.
Who are the major players in the brucellosis market? +
HESTER BIOSCIENCES LIMITED (India), Merck & Co., Inc. (United States), and Dollvet (Turkey) are some of the major players in the market.
How big is the brucellosis market? +
In 2024, the brucellosis market is USD 303.46 million.
Which is the fastest-growing region in the brucellosis market? +
Asia Pacific is the fastest-growing region in the brucellosis market.
What specific segmentation details are covered in the brucellosis market? +
Species, Type, and End-User are covered in the brucellosis market.
Who are the major players in the brucellosis market? +
HESTER BIOSCIENCES LIMITED (India), Merck & Co., Inc. (United States), and Dollvet (Turkey) are some of the major players in the market.
